Develops cancer vaccines and cell therapies for non-muscle invasive bladder cancer and non-small cell lung cancer.
Jun 2026Revenue $166M/yrExpenses $418M/yr
Expected break-even Jul 2027Cash runway ≈ 1.2 years from Jun 2026
Figures by year
When will ImmunityBio be profitable?
Its revenue and expense trends are projected to cross in Jul 2027. In the 12 months to Jun 2026, revenue was $166M and expenses $418M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $113M | $369M | −$256M |
| Dec 2024 | $14.7M | $359M | −$344M |
| Dec 2023 | $622K | $363M | −$362M |
| Dec 2022 | $240K | $352M | −$351M |
| Dec 2021 | $934K | $331M | −$330M |
| Dec 2020 | $605K | $221M | −$221M |
| Dec 2019 | $2.20M | $158M | −$156M |
| Dec 2018 | $47.0K | $98.4M | −$98.4M |
| Dec 2017 | $45.0K | $99.2M | −$99.1M |
| Dec 2016 | $44.0K | $125M | −$125M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.